News - Impax Laboratories


Current filters:

Impax Laboratories

Popular Filters

Impax Pharma resubmits NDA for Rytary

Impax Pharma resubmits NDA for Rytary


Impax Laboratories’ branded products division has resubmitted the New Drug Application for Rytary (carbidopa…

Impax LaboratoriesNeurologicalNorth AmericaPharmaceuticalRegulationRytaryUSA

Impax and DURECT in $63 million deal for Eladur pain patch


US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

Patent expiries will push Parkinson’s drug market lower by 2019


Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta


US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Generic versions of Trilipix debut in USA; Mylan sued by UCB


Impax Laboratories (Nasdaq: IPXL) today announced yesterday (July 15) that it is commencing shipment…

AbbVieCardio-vascularGenericsImpax LaboratoriesLegalMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaPatentsTripilixUCBVimpat

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz


US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

Impax launches authorized generic of Zomig, as Mylan debuts copy of Tricor in USA


US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals,…

AbbVieAstraZenecaCardio-vascularGenericsImpax LaboratoriesMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaTricorZomig

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug


US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study


Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

Another stumbling block for Impax Pharma's Rytary


Impax Pharmaceuticals, the branded products division of Impax Laboratories (Nasdaq: IPXL), revealed on…

GlaxoSmithKlineImpax LaboratoriesNeurologicalNorth AmericaPharmaceuticalProductionRegulationRytary

Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion


The US District Judge Reggie Walton, of the District Court for the District of Columbia, has dismissed…

ActavisComtanEndo PharmaceuticalsGenericsImpax LaboratoriesLegalMylan LaboratoriesNeurologicalNorth AmericaOpana ERPharmaceutical

Impax in deal with Perrigo; Cipla eyes South Africa acquisition


Impax Laboratories (Nasdaq: IPXL) said yesterday that it plans to collaborate with fellow US drugmaker…

CiplaCipla MedproGenericsImpax LaboratoriesMarkets & MarketingMergers & AcquisitionsNorth AmericaPerrigoResearchRest of the World

Impax Labs and Teva settle Concerta litigation with J&J units


USA-based Impax Laboratories (Nasdaq: IPXL) and the US unit of Israel generics giant Teva Pharmaceutical…

ALZA CorpConcertaGenericsImpax LaboratoriesJanssenJohnson & JohnsonNeurologicalNorth AmericaPatentsTeva Pharmaceutical Industries

Impax Labs settles with Genzyme over Renvela and Renagel generics


USA-based Impax Laboratories (Nasdaq: IPXL) says it has reached agreement with French drug major Sanofi's…

GenzymeImpax LaboratoriesPatentsPharmaceuticalRenagelRenvelaSanofi

Impax and Tolmar enter generic drug distribution deal


US generic drugmaker Impax Laboratories (Nasdaq: IPXL) has entered into a collaboration with contract…

GenericsImpax LaboratoriesLicensingMarkets & MarketingResearchTolmar

Mylan debuts Lescol copy; Impax challenges Gralise patent


US generic drug major Mylan (Nasdaq: MYL) revealed last Friday that it has begun shipping its generic…

Cardio-vascularDepomedGenericsGraliseImpax LaboratoriesLescolMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaNovartisPatentsRegulation

Impax buys US rights to Zomig


Impax Pharmaceuticals, the branded products business unit of Impax Laboratories (Nasdaq: IPXL) has licensed…

AstraZenecaImpax LaboratoriesLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalZomig

Perrigo confirms ANDA filing for generic Astepro nasal spray


US generic drugmaker Perrigo (Nasdaq: PRGO;TASE) says that it has filed an Abbreviated New Drug Application…

AsteproAzelastine HydrochlorideGenericsImpax LaboratoriesLegalMedaNorth AmericaPatentsPerrigoRegulationRespiratory and Pulmonary

Impax confirms patent challenge to GlaxoSmithKline’s Jalyn; Albemarle hikes API prices


US generic drugmaker Impax Laboratories (Nasdaq: IPXL) confirms that it has initiated a challenge of…

AlbemarleAvodartGenericsGlaxoSmithKlineImpax LaboratoriesJalynLegalNorth AmericaPatentsPricing

Exec appointments at SkyePharma, Impax, Ariad and Regeneron


UK-based drug delivery specialist SkyePharma (LSE: SKP) has appointed Pierre Delavaud as executive vice…

Ariad PharmaceuticalsGenericsImpax LaboratoriesManagementPharmaceuticalRegeneronSkyepharma

Positive top-line Ph III results of Impax and GSK IPX066 in advanced Parkinson’s disease


USA-based Impax Pharmaceuticals, the branded products division of Impax Laboratories, (Nasdaq: IPXL),…

GlaxoSmithKlineImpax LaboratoriesNeurologicalPharmaceuticalResearch

Back to top